<DOC>
	<DOCNO>NCT02588456</DOCNO>
	<brief_summary>This single center , single arm , open-label pilot study determine feasibility safety single dose autologous T cell express CD22 chimeric antigen receptor express tandem TCRζ 4-1BB ( TCRζ/4-1BB ) co-stimulatory domain ( refer `` CART22 '' cell ) administer split fraction , adult patient relapse refractory B-cell acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Pilot Study Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<criteria>1 . Signed informed consent form must obtain prior research procedure . 2 . Relapsed refractory Bcell ALL : . 1st great BM relapse OR b . Any marrow relapse allogeneic HSCT &gt; 100 day transplant OR c. For patient refractory disease : . &lt; 60 year old achieve CR &gt; 2 chemotherapy regimen ii . &gt; 60 year old achieve CR 1 prior chemotherapy regimen d. Patients Ph+ ALL eligible intolerant fail tyrosine kinase inhibitor therapy . e. Patients CNS3 disease eligible CNS disease responsive therapy . 3 . Documentation CD22 expression malignant cell relapse . 4 . Adequate organ function define : 1 . Creatinine &lt; 1.6 mg/dl 2 . ALT/AST &lt; 3x upper limit normal range 3 . Direct bilirubin &lt; 2.0 mg/dl 4 . Must minimum level pulmonary reserve define ≤ Grade 1 dyspnea , pulse oxygen &gt; 92 % room air , DLCO &gt; 40 % ( correct anemia ) 5 . Left Ventricle Ejection Fraction ( LVEF ) ≥ 40 % confirm ECHO/MUGA 5 . Evidence disease standard morphologic MRD criterion . 6 . Male female age ≥ 18 year . 7 . ECOG Performance Status either 0 1 . 8 . No contraindication leukapheresis . 9 . Subjects reproductive potential must agree use acceptable birth control method . 1 . Active hepatitis B active hepatitis C. 2 . HIV Infection . 3 . Class III/IV cardiovascular disability accord New York Heart Association Classification . 4 . Subjects clinically apparent arrhythmia arrhythmia stable medical management within two week enrollment . 5 . Active acute chronic graftversushost disease ( GVHD ) require systemic therapy . 6 . Concurrent use systemic steroid immunosuppressant medication . Recent current use inhale steroid physiologic replacement hydrocortisone exclusionary . For additional detail regard use steroid immunosuppressant medication . 7 . CNS3 disease progressive therapy , CNS parenchymal lesion might increase risk CNS toxicity . 8 . Pregnant nursing ( lactate ) woman . 9 . Receipt prior investigational study agent within 4 week prior enrollment . *Note patient receive antiCD19 CART cell ( e.g . CART19/CTL019 ) investigational study cell infusion occur great 4 week screen visit NOT exclude . 10 . Patients known history prior diagnosis optic neuritis immunologic inflammatory disease affect central nervous system .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>